susan-froshauer-150px_w_outline

Susan Froshauer, Ph.D.

Yale Entrepreneur-in-Residence                                                   Vice President, CURE Collaborations LLC
Past President & CEO, CURE

Dr. Froshauer has joined Yale Office of Cooperative Research as an Entrepreneur in Residence, returning to one of her passions, connecting entrepreneurs to know-how, funding and approaches that ultimately may improve our quality of life. Susan is also a leader of the CURE Commons accelerator programs, especially assisting with a Thames River community entrepreneur outreach as part of a CTNext Innovation Places funded program, Ignite. She recently stepped-down from her role as President and CEO of CURE in order to better focus her time as a tech/biotech start-up executive. She is an experienced scientist, mentor, entrepreneur and angel investor with skill at connecting academic expertise and technology with the commercial sector. Susan serves on the Boards of Carogen, LambdaVision, Bioxiness, Thames River Innovation Partners and is a business advisor to Alva Health and HLK Pharma. In addition to CURE and the Yale Entrepreneurial Institute, Susan has been involved with the CTNext funded group, SECT Tech, the Creative Arts Workshop and the Angel Investor Forum. Prior to joining CURE, Dr. Froshauer was Director of the Technology Exchange Portal at the University of Connecticut’s Office of Economic Development. In this role, Susan assisted Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connected ideas with business expertise, business plans with investors and industry with scholars. Until 2010, Susan served for 11 years as the founding President and CEO of Rib-X Pharmaceuticals (now Melinta), which she co-founded in New Haven in 2000. Under her leadership, Rib-X raised more than $160 million in private equity, bridge financing and government grants and built an emerging pipeline of antibiotics to treat serious hospital infections. Melinta is launching its first product as it goes public in the next few weeks. Prior to Rib-X, Susan served as a member of Pfizer’s Strategic Alliance Groups where she was part of a team involved in the creation of a $200 million investment portfolio that at the time transformed the Pfizer global research and development strategy. She received a Ph.D. in Microbiology and Molecular Genetics from Harvard University and a B.A. from Connecticut College. She performed post-doctoral research at Yale Medical School in the Department of Cell Biology as a Jane Coffin Child’s Fellow.